Deflazacort
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 315341

CAS#: 14484-47-0

Description: Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant. It is sold in the United Kingdom by Shire under the trade name Calcort. in Brazil as Cortax, Decortil, and Deflanil, and in Honduras as Flezacor. It is not available in the United States. Deflazacort is a prodrug. Its potency is around 70–90% that of prednisone.


Chemical Structure

img
Deflazacort
CAS# 14484-47-0

Theoretical Analysis

MedKoo Cat#: 315341
Name: Deflazacort
CAS#: 14484-47-0
Chemical Formula: C25H31NO6
Exact Mass: 441.21514
Molecular Weight: 441.51674
Elemental Analysis: C, 68.01; H, 7.08; N, 3.17; O, 21.74

Price and Availability

Size Price Availability Quantity
1.0g USD 250.0 2 Weeks
2.0g USD 450.0 2 Weeks
5.0g USD 850.0 2 Weeks
Bulk inquiry

Synonym: Azacort; Calcort; Deflan; Cortax; DL-458-IT; DL 458-IT; DL458-IT; Emflaza; Enzocort; Flantadin; L-5458; Lantadin; MDL 458; MDL-458; MDL458; Oxazacort;

IUPAC/Chemical Name: 2-((6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-6a,8a,10-trimethyl-4-oxo-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d]oxazol-8b-yl)-2-oxoethyl acetate

InChi Key: FBHSPRKOSMHSIF-GRMWVWQJSA-N

InChi Code: InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1

SMILES Code: CC(OCC([C@@]12N=C(C)O[C@]1([H])C[C@@]3([H])[C@@](CCC4=CC(C=C[C@@]45C)=O)([H])[C@]5([H])[C@@H](O)C[C@@]32C)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 441.51674 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: McDonald CM, Sajeev G, Yao Z, McDonnell E, Elfring G, Souza M, Peltz SW, Darras BT, Shieh PB, Cox DA, Landry J, Signorovitch J; ACT DMD Study Group and the Tadalafil DMD Study Group. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials. Muscle Nerve. 2019 Oct 10. doi: 10.1002/mus.26736. [Epub ahead of print] PubMed PMID: 31599456.

2: Kucukpolat S, Kocaaslan R, Kadihasanoglu M, Bagcioglu M, Kocan H, Sarica K. Is Medical Therapy for Distal Ureteral Stones Efficient? Tamsulosin versus Deflazacort: A Prospective Randomised Trial. Aktuelle Urol. 2019 Sep 19. doi: 10.1055/a-0770-2627. [Epub ahead of print] PubMed PMID: 31537025.

3: Tantawy MA, Alweshahy S, Elshabasy DA, Youssef NF. Simultaneous Determination of Co-administrated Deflazacort, Aprepitant and Granisetron in Dosage Forms and Spiked Human Plasma by RP-HPLC/PAD. J Chromatogr Sci. 2019 Aug 28. pii: bmz062. doi: 10.1093/chromsci/bmz062. [Epub ahead of print] PubMed PMID: 31504281.

4: Yun BH, Joo DJ, Seo SK, Cho SH, Choi YS, Lee BS. Effect of deflazacort on pregnancy outcome in kidney transplant patients: should we change the immunosuppressant before conception? BMC Nephrol. 2019 May 14;20(1):161. doi: 10.1186/s12882-019-1346-6. PubMed PMID: 31088388; PubMed Central PMCID: PMC6515635.

5: Fappi A, Neves JC, Sanches LN, Massaroto E Silva PV, Sikusawa GY, Brandão TPC, Chadi G, Zanoteli E. Skeletal Muscle Response to Deflazacort, Dexamethasone and Methylprednisolone. Cells. 2019 May 1;8(5). pii: E406. doi: 10.3390/cells8050406. PubMed PMID: 31052442; PubMed Central PMCID: PMC6562646.

6: Trujillo-Trujillo MJ, González-Mancebo E, Gandolfo-Cano M, Mohedano-Vicente E, Martínez-Morán C. Deflazacort-Induced Erythema Multiforme Exudativum Successfully Treated With a Single Dose of Etanercept. J Investig Allergol Clin Immunol. 2018 Oct;28(5):338-339. doi: 10.18176/jiaci.0277. PubMed PMID: 30350788.

7: Sardana K, Bajaj S, Bose SK. Successful treatment of PAPA syndrome with minocycline, dapsone, deflazacort and methotrexate: a cost-effective therapy with a 2-year follow-up. Clin Exp Dermatol. 2019 Jul;44(5):577-579. doi: 10.1111/ced.13792. Epub 2018 Sep 26. PubMed PMID: 30259545.

8: Shieh PB, Mcintosh J, Jin F, Souza M, Elfring G, Narayanan S, Trifillis P, Peltz SW, Mcdonald CM, Darras BT; THE ACT DMD STUDY GROUP. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial. Muscle Nerve. 2018 Nov;58(5):639-645. doi: 10.1002/mus.26191. Epub 2018 Sep 27. PubMed PMID: 30028519; PubMed Central PMCID: PMC6767037.

9: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500900/ PubMed PMID: 29999959.

10: Hussar DA, Bailey KJ. Semaglutide, Ertugliflozin, and Deflazacort. J Am Pharm Assoc (2003). 2018 May - Jun;58(3):321-325. doi: 10.1016/j.japh.2018.04.005. PubMed PMID: 29739505.

11: Bashir MSM, Saleem M, Choudhari U. Deflazacort-induced Acneiform Eruptions. J Pharm Bioallied Sci. 2017 Oct-Dec;9(4):284-286. doi: 10.4103/jpbs.JPBS_67_17. PubMed PMID: 29456382; PubMed Central PMCID: PMC5810081.

12: Ganapati A, Ravindran R, David T, Yadav B, Jeyaseelan V, Jeyaseelan L, Danda D. Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study. Lupus. 2018 Jan 1:961203317751854. doi: 10.1177/0961203317751854. [Epub ahead of print] PubMed PMID: 29320974.

13: de Carvalho SC, Matsumura CY, Santo Neto H, Marques MJ. Identification of plasma interleukins as biomarkers for deflazacort and omega-3 based Duchenne muscular dystrophy therapy. Cytokine. 2018 Feb;102:55-61. doi: 10.1016/j.cyto.2017.12.006. Epub 2017 Dec 22. PubMed PMID: 29276972.

14: Chrzanowski SM, Poudyal R. Deflazacort-New Costs of an Old Medicine. JAMA Neurol. 2018 Feb 1;75(2):143-144. doi: 10.1001/jamaneurol.2017.3704. PubMed PMID: 29228076.

15: Deflazacort (Emflaza) for Duchenne muscular dystrophy. Med Lett Drugs Ther. 2017 Sep 11;59(1529):153-154. PubMed PMID: 28880848.

16: Pereira JA, Mauricio AF, Marques MJ, Neto HS. Dual Therapy Deflazacort/Doxycyclyne Is Better Than Deflazacort Monotherapy to Alleviate Cardiomyopathy in Dystrophin-Deficient mdx Mice. J Cardiovasc Pharmacol Ther. 2017 Sep;22(5):458-466. doi: 10.1177/1074248416686189. Epub 2016 Dec 28. PubMed PMID: 28793824.

17: Gupta N, Ganpati A, Mandal S, Mathew J, Goel R, Mathew AJ, Nair A, Ramasamy P, Danda D. Mycophenolate mofetil and deflazacort combination in neuropsychiatric lupus: a decade of experience from a tertiary care teaching hospital in southern India. Clin Rheumatol. 2017 Oct;36(10):2273-2279. doi: 10.1007/s10067-017-3775-6. Epub 2017 Aug 7. PubMed PMID: 28785855.

18: Escudero AI, Marín P, Cárceles CM, Escudero E. Pharmacokinetics of deflazacort in rabbits after intravenous and oral administration and its interaction with erythromycin. J Vet Pharmacol Ther. 2018 Feb;41(1):e10-e15. doi: 10.1111/jvp.12442. Epub 2017 Jul 25. PubMed PMID: 28741668.

19: Jensen L, Petersson SJ, Illum NO, Laugaard-Jacobsen HC, Thelle T, Jørgensen LH, Schrøder HD. Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophy. J Musculoskelet Neuronal Interact. 2017 Jun 1;17(2):8-18. PubMed PMID: 28574407; PubMed Central PMCID: PMC5492315.

20: Deshmukh R, Sharma L, Tekade M, Kesharwani P, Trivedi P, Tekade RK. Force degradation behavior of glucocorticoid deflazacort by UPLC: isolation, identification and characterization of degradant by FTIR, NMR and mass analysis. J Biomed Res. 2016 Mar;30(2):149-161. doi: 10.7555/JBR.30.20150074. Epub 2016 Feb 20. PubMed PMID: 28276670; PubMed Central PMCID: PMC4820892.